Business Wire3h
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and ...
Business Wire5h
Friday, December 27, 2024 9:55AM IST (4:25AM GMT)
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor ... LED उत्पादों और प्रौद्योगिकी के एक अग्रणी वैश्विक प्रर्वतक, Seoul Semiconductor Co., Ltd. (KOSDAQ: ...